Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar.

Tuberculosis (Edinburgh, Scotland) - 1 Dec 2020

Ei Phyu Win, Mon Aye Su, Htwe Mi Mi, Win Su Mon, Aye Kay Thi, San Lai Lai, Zaw Ni Ni, Nyunt Wint Wint, Myint Zaw, Lee Jong Seok, Aung Wah Wah

Abstract excerpt

Pyrazinamide (PZA) is an important anti-tuberculosis drug, which is active against semi-dormant bacilli and used as a component of first-line drugs and drug-resistant tuberculosis regimens. Mutations in pncA and its promoter region are main cause of PZA resistance. There are limited PZA susceptibility data as there is no routine drug susceptibility testing (DST) for PZA. This study was aimed to determine the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to DNA, Bacterial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Bacterial

Share to Incidence

Share to Myanmar

Share to Mycobacterium tuberculosis

Share to Pyrazinamide

Share to Tuberculosis, Multidrug-Resistant

Source

Identifiers

PMID: 33142220
DOI: 10.1016/j.tube.2020.102013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar.PMID 33142220Read ↗

High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.Semantic proximity Read ↗

Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium TuberculosisSemantic proximity Read ↗

Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates.Semantic proximity Read ↗

Pyrazinamide resistance due to pncA gene mutation and its association with treatment outcome among tuberculosis patients of South India- A longitudinal observational study.Semantic proximity Read ↗

pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of BrazilSemantic proximity Read ↗

Mutations Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis: A Review and Update.Semantic proximity Read ↗

Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates.Semantic proximity Read ↗

Pyrazinamide Susceptibility and pncA Mutation Profiles of Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Patients in Bangladesh.Semantic proximity Read ↗

Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.Semantic proximity Read ↗

Genotypic characterization of pyrazinamide resistance in Mycobacterium tuberculosis isolated from Lusaka, Zambia.Semantic proximity Read ↗

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.Semantic proximity Read ↗

Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.